We partner with pharmaceutical and biotech companies, physicians and patients to advance the science of cancer treatments.
Sarah Cannon Research Institute (SCRI) is a global leader in oncology research, conducting clinical trials in the community for more than 30 years. In 2022, SCRI formed a joint venture with former US Oncology Research to expand clinical trial access across the country. Our contributions to pivotal research have helped to advance the majority of new cancer therapies approved by the FDA today.
1,300+ research physicians
250+ locations in 24 States. Our research network reaches 1 In 5 patients with cancer through our affiliated sites
1,000 + trials actively enrolling
4,500+ registered patients participating in trials yearly
Conducted nearly 700 first-in-human trials since inception
SCRI is the only oncology research organization of its kind to offer end-to-end clinical trial site management, contract research services for biopharma and personalized medicine advisory services in one place:
As CEO of SCRI, Dee Anna Smith leads the organization’s overall mission and vision to make a global impact on the next generation of cancer care.
Dr. Burris joined SCRI in 1997 to create the first drug development program outside of an academic setting and oversees all of SCRI’s clinical operations and research strategies. An oncology key opinion leader and former ASCO president, Dr. Burris has influenced new cancer treatment standards for more than 3 decades.
Dr. Spigel joined SCRI in 2003, and, as chief scientific officer, he oversees all scientific aspects of SCRI’s clinical trial program, working with the research physician leaders to ensure the best new agents and studies are available to our patients.